Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 413

1.

Phase II study of ketoconazole plus granulocyte-macrophage colony-stimulating factor for prostate cancer: effect of extent of disease on outcome.

Ryan CJ, Weinberg V, Rosenberg J, Fong L, Lin A, Kim J, Small EJ.

J Urol. 2007 Dec;178(6):2372-6; discussion 2377. Epub 2007 Oct 22.

PMID:
17936834
2.

Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy.

Urba WJ, Nemunaitis J, Marshall F, Smith DC, Hege KM, Ma J, Nguyen M, Small EJ.

J Urol. 2008 Nov;180(5):2011-7; discussion 2017-8. doi: 10.1016/j.juro.2008.07.048. Epub 2008 Sep 17.

PMID:
18801509
3.

Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer.

Harris KA, Weinberg V, Bok RA, Kakefuda M, Small EJ.

J Urol. 2002 Aug;168(2):542-5.

PMID:
12131305
4.

A phase II trial of bortezomib and prednisone for castration resistant metastatic prostate cancer.

Morris MJ, Kelly WK, Slovin S, Ryan C, Eicher C, Heller G, Scher HI.

J Urol. 2007 Dec;178(6):2378-83; discussion 2383-4. Epub 2007 Oct 22.

PMID:
17936848
5.

Phase 2 study of granulocyte-macrophage colony-stimulating factor plus thalidomide in patients with hormone-naïve adenocarcinoma of the prostate.

Amato RJ, Hernandez-McClain J, Henary H.

Urol Oncol. 2009 Jan-Feb;27(1):8-13. doi: 10.1016/j.urolonc.2007.10.014. Epub 2008 Jan 14.

PMID:
18367123
6.

Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.

James ND, Caty A, Borre M, Zonnenberg BA, Beuzeboc P, Morris T, Phung D, Dawson NA.

Eur Urol. 2009 May;55(5):1112-23. doi: 10.1016/j.eururo.2008.11.002. Epub 2008 Nov 29.

PMID:
19042080
7.

Long-term outcome for men with androgen independent prostate cancer treated with ketoconazole and hydrocortisone.

Scholz M, Jennrich R, Strum S, Brosman S, Johnson H, Lam R.

J Urol. 2005 Jun;173(6):1947-52.

PMID:
15879788
8.
9.

Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor.

Small EJ, Reese DM, Um B, Whisenant S, Dixon SC, Figg WD.

Clin Cancer Res. 1999 Jul;5(7):1738-44.

10.

A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America.

Gittelman M, Pommerville PJ, Persson BE, Jensen JK, Olesen TK; Degarelix Study Group..

J Urol. 2008 Nov;180(5):1986-92. doi: 10.1016/j.juro.2008.07.033. Epub 2008 Sep 17.

PMID:
18801505
11.
12.
13.

Phase II study of mitoxantrone and ketoconazole for hormone-refractory prostate cancer.

Eklund J, Kozloff M, Vlamakis J, Starr A, Mariott M, Gallot L, Jovanovic B, Schilder L, Robin E, Pins M, Bergan RC.

Cancer. 2006 Jun 1;106(11):2459-65.

14.

Testosterone recovery after prolonged androgen suppression in patients with prostate cancer.

Yoon FH, Gardner SL, Danjoux C, Morton G, Cheung P, Choo R.

J Urol. 2008 Oct;180(4):1438-43; discussion 1443-4. doi: 10.1016/j.juro.2008.06.029. Epub 2008 Aug 16.

PMID:
18710743
15.

Granulocyte macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer.

Small EJ, Sacks N, Nemunaitis J, Urba WJ, Dula E, Centeno AS, Nelson WG, Ando D, Howard C, Borellini F, Nguyen M, Hege K, Simons JW.

Clin Cancer Res. 2007 Jul 1;13(13):3883-91.

17.
18.

Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.

Koutsilieris M, Mitsiades CS, Bogdanos J, Dimopoulos T, Karamanolakis D, Milathianakis C, Tsintavis A.

Clin Cancer Res. 2004 Jul 1;10(13):4398-405.

19.

Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.

Demanes DJ, Brandt D, Schour L, Hill DR.

Am J Clin Oncol. 2009 Aug;32(4):342-7. doi: 10.1097/COC.0b013e31818cd277.

PMID:
19398902
20.

Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial.

Burch PA, Croghan GA, Gastineau DA, Jones LA, Kaur JS, Kylstra JW, Richardson RL, Valone FH, Vuk-Pavlović S.

Prostate. 2004 Aug 1;60(3):197-204.

PMID:
15176049

Supplemental Content

Support Center